Last reviewed · How we verify
Intravenous Formulation of PD-0332991 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Intravenous Formulation of PD-0332991 (Intravenous Formulation of PD-0332991) — Pfizer.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intravenous Formulation of PD-0332991 TARGET | Intravenous Formulation of PD-0332991 | Pfizer | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intravenous Formulation of PD-0332991 CI watch — RSS
- Intravenous Formulation of PD-0332991 CI watch — Atom
- Intravenous Formulation of PD-0332991 CI watch — JSON
- Intravenous Formulation of PD-0332991 alone — RSS
Cite this brief
Drug Landscape (2026). Intravenous Formulation of PD-0332991 — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-formulation-of-pd-0332991. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab